{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:51:49Z","timestamp":1781653909821,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 67-year-old man presented with bilateral diplopia and gait instability. Brain magnetic resonance imaging revealed two adjacent lesions in the right middle cerebellar peduncle: a 2.7-cm cystic lesion with an enhancing mural nodule and a 1.7-cm ring-enhancing nodule with surrounding edema and associated brainstem compression. Biopsy followed by surgical resection demonstrated a biphasic tumor composed of glioma-like and epithelial-like components. Immunohistochemically, the glioma-like component expressed GFAP and OLIG2, whereas the epithelial-like component lacked glial and epithelial lineage markers and exhibited a high proliferative index (Ki-67 labeling index, 50%). Aberrant calponin-1 expression was observed in both components but was not associated with definitive smooth muscle or myoepithelial differentiation. DNA methylation profiling did not yield a definitive classification and demonstrated borderline similarity to established high-grade glioma classes, clustering near the glioblastoma, IDH-wild-type, midline subtype. Molecular analysis of the epithelial-like component was not feasible due to limited tissue availability, preventing assessment of clonal relatedness between components. This case illustrates the diagnostic challenges posed by intratumoral heterogeneity and sampling limitations in adult cerebellar high-grade gliomas. This report highlights the interpretive constraints of current histopathological and molecular classification frameworks when confronted with spatially heterogeneous tumors and incomplete sampling, rather than defining a novel tumor entity.<\/jats:p>","DOI":"10.1007\/s10014-026-00537-3","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:20:35Z","timestamp":1777432835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biphasic high-grade cerebellar glioma with epithelial-like components: challenges in integrated diagnosis imposed by limited sampling"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2355","authenticated-orcid":false,"given":"Yasuhide","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Mineharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaishi","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M et al (2018) DNA methylation-based classification of Central Nervous System tumours. Nature 555:469\u2013474","journal-title":"Nature"},{"key":"537_CR2","unstructured":"Louis DN, CWKEDWF-BDOHPARGVDAWOD (2016) WHO classification of tumours of the central nervous system. IARC, France"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-019-0801-8","volume":"7","author":"A Reinhardt","year":"2019","unstructured":"Reinhardt A, Stichel D, Schrimpf D et al (2019) Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol Commun 7:163","journal-title":"Acta Neuropathol Commun"},{"key":"537_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12843","volume":"48","author":"Y Takeuchi","year":"2022","unstructured":"Takeuchi Y, Mineharu Y, Arakawa Y et al (2022) A novel SREBF1::NACC1 gene fusion in an unclassifiable intracranial tumour. Neuropathol Appl Neurobiol 48:e12843","journal-title":"Neuropathol Appl Neurobiol"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ng894","volume":"31","author":"DV Bulavin","year":"2002","unstructured":"Bulavin DV, Demidov ON, Saito S et al (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31:210\u2013215","journal-title":"Nat Genet"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1541-7786.MCR-21-1018","volume":"20","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hsu JI, Goodell MA (2022) PPM1D in solid and hematologic malignancies: friend and foe? Mol Cancer Res 20:1365\u20131378","journal-title":"Mol Cancer Res"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1186\/s12885-021-08733-4","volume":"21","author":"Y Makino","year":"2021","unstructured":"Makino Y, Arakawa Y, Yoshioka E et al (2021) Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer 21:1025","journal-title":"BMC Cancer"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/neup.13016","volume":"45","author":"K Satomi","year":"2025","unstructured":"Satomi K, Shibayama T, Hibiya T et al (2025) MYB::QKI fusion-positive diffuse glioma of the cerebellum: a case report. Neuropathology 45:228\u2013233","journal-title":"Neuropathology"},{"key":"537_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1184250","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Ke J, Liu C et al (2023) Potential prognostic and immunotherapeutic value of calponin 1: a pan-cancer analysis. Front Pharmacol 14:1184250","journal-title":"Front Pharmacol"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1440-1827.1998.tb03956.x","volume":"48","author":"H Horiguchi","year":"1998","unstructured":"Horiguchi H, Hirose T, Kannuki S et al (1998) Gliosarcoma: an immunohistochemical, ultrastructural and fluorescence in situ hybridization study. Pathol Int 48:595\u2013602","journal-title":"Pathol Int"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251","journal-title":"Neuro Oncol"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-026-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-026-00537-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-026-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:54:31Z","timestamp":1781650471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-026-00537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":11,"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1007\/s10014-026-00537-3","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.M. reported grants from Omron Healthcare. Y.A. reported grants from Otsuka, Chugai, Nihon Medi-Physics, Daiichi Sankyo, Stryker, Eisai, Japan Blood Products Organization, Ono Pharmaceutical, Taiho Pharma, Sumitomo Dainippon Pharma, Astellas Pharma, and Sanofi and personal fees from Nippon Kayaku, Novocure, UCB Japan, Ono Pharmaceutical, Brainlab, Merck, Chugai, Eisai, Daiichi Sankyo, Carl Zeiss, and Nihon Medi-Physics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}